SCHEMBL390338

SCHEMBL390338

COC(=O)c1ccnc(N2CCN(C(=O)OCC(C)(C)C)CC2)c1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HRH3 Q9Y5N1 2/20 0.56
PIK3CA P42336 2/20 0.50
MEN1 O00255 1/20 0.44
KMT2A Q03164 1/20 0.44
KDM4E B2RXH2 2/20 0.44
POLB P06746 1/20 0.44
L3MBTL1 Q9Y468 1/20 0.44
KDM4C Q9H3R0 2/20 0.42
KDM6B O15054 1/20 0.42
KDM5C P41229 1/20 0.42
KDM2A Q9Y2K7 1/20 0.42
KDM3A Q9Y4C1 1/20 0.42
KDM5A P29375 3/20 0.42
KDM5B Q9UGL1 3/20 0.42
HPGD P15428 1/20 0.42
SMN1; SMN2 Q16637 1/20 0.42
PHGDH O43175 1/20 0.41
JMJD6 Q6NYC1 1/20 0.41
OPRD1 P41143 1/20 0.41
KCNH2 Q12809 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14340961 0.87 MAPT (0.49) HRH3PIK3CAMEN1KMT2AKDM4E
SCHEMBL20938625 0.85 HRH3 (0.59) HRH3PIK3CAMEN1KMT2AKDM4E
SCHEMBL390340 0.84 HRH3 (0.54) HRH3MEN1KMT2AKDM4EL3MBTL1
SCHEMBL389881 0.84 PIK3CA (0.43) HRH3PIK3CAKDM4EHPGDSMN1; SMN2
SCHEMBL389882 0.84 PIK3CA (0.43) HRH3PIK3CAKDM4EHPGDSMN1; SMN2
SCHEMBL390651 0.84 NOS1 (0.49) PIK3CAMEN1KMT2AKDM4EPOLB
SCHEMBL390540 0.83 OPRD1 (0.57) HRH3PIK3CAHPGDSMN1; SMN2OPRD1
SCHEMBL387328 0.83 GRIN2D (0.47) HRH3MEN1KMT2AKDM4EHPGD
SCHEMBL387385 0.82 HTT (0.43) HRH3PIK3CAMEN1KMT2AKDM4E
SCHEMBL388764 0.82 GRIN2D (0.49) MEN1KMT2AKDM4EPOLBHPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090062293-A1 1,4-Substituted Piperazine Derivatives MSD K.K. (JP) 2009-03-05 US claimed
EP-1870401-A1 1,4-SUBSTITUTED PIPERAZINE DERIVATIVE BANYU PHARMACEUTICAL CO., LTD. (JP) 2007-12-26 EP claimed
US-8101618-B2 1,4-substituted piperazine derivatives MSD K.K. (JP) 2012-01-24 US disclosed
US-8101618-B2 1,4-substituted piperazine derivatives MSD K.K. (JP) 2012-01-24 US disclosed
US-8101618-B2 1,4-substituted piperazine derivatives MSD K.K. (JP) 2012-01-24 US disclosed
US-20090062293-A1 1,4-Substituted Piperazine Derivatives MSD K.K. (JP) 2009-03-05 US disclosed
US-20090062293-A1 1,4-Substituted Piperazine Derivatives MSD K.K. (JP) 2009-03-05 US disclosed
US-20090062293-A1 1,4-Substituted Piperazine Derivatives MSD K.K. (JP) 2009-03-05 US disclosed
EP-1870401-A1 1,4-SUBSTITUTED PIPERAZINE DERIVATIVE BANYU PHARMACEUTICAL CO., LTD. (JP) 2007-12-26 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090062293-A1 1,4-Substituted Piperazine Derivatives GRIN1, GRM1, GRIN2C HRH3 661/4885PIK3CA 3823/4885MEN1 4558/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.